• Profile
Close

Incidence of thyroid function test abnormalities in patients receiving immune-checkpoint inhibitors for cancer treatment

The Oncologist May 23, 2018

Patel NS, et al. - Authors ascertained the incidence of thyroid function test abnormalities (TFTAs) retrospectively in patients who received immune-checkpoint inhibitor (ICI) therapy for cancer treatment. Findings suggested a higher incidence of TFTAs with ICI therapy than previously reported. Compared to patients receiving single-agent ICI therapy, a higher incidence of TFTAs was seen in patients with baseline TFTAs and/or who were receiving ipilimumab and nivolumab combination therapy. Especially in patients with baseline TFTAs, more frequent evaluation of thyroid function in the first 8 weeks was suggested.
Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay